Repetitive Transcranial Magnetic Stimulation Combined With Median Nerve Electrical Stimulation for Severe Traumatic Brain Injury.

Brain BehavSep 30, 2026
Clinical ResearchNeurologyPhysical Medicine & Rehabilitation

Nana Wang, Manrong Li, Guozhen Zhang

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the effects of repetitive transcranial magnetic stimulation (rTMS) combined with median nerve electrical stimulation (MNS) in 86 patients with severe traumatic brain injury (sTBI) and coma. The combination therapy resulted in significantly higher awakening efficacy (92.86%) compared to rTMS (65.52%) and MNS (62.07%) at week 4 (p < 0.05).

Key findings

  • Combination therapy achieved 92.86% awakening efficacy compared to 65.52% for rTMS and 62.07% for MNS (p < 0.05).
  • The combination group showed the greatest GCS improvement (Δ+6.04) compared to MNS (Δ+4.50) and rTMS (Δ+4.19).
  • 71.4% of the combination group achieved EEG normalization to Grade I-II by week 4, the highest among groups.
  • Adverse event rates were low across all groups, with no seizures reported.

Why it matters

The study highlights the potential of combining rTMS and MNS as a dual-pathway approach to enhance recovery of consciousness in patients with severe traumatic brain injury, a condition often associated with poor outcomes.

Source

PubMed · PMID 42806603

Published in Brain Behav. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.